Amai Proteins Achieves Landmark with World's First Human Trial on Sweet Proteins
Amai Proteins, based in Rehovot, Israel, has announced a groundbreaking achievement in the nutritional science sector with the successful completion of the first-ever human clinical trial examining the effects of their proprietary sweet protein, sweelin®. Conducted under strict Good Clinical Practice guidelines at the Tel Aviv Sourasky Medical Center, this double-blind, randomized controlled trial set out to determine the impact of sweelin® on blood glucose and insulin levels in healthy adults.
The study involved twenty healthy participants who underwent three test sessions, during which they consumed beverages sweetened with either sweelin®, glucose, or stevia. Each beverage was meticulously matched for sweetness, equivalent to 75 grams of glucose commonly used in Oral Glucose Tolerance Tests. For 120 minutes post-consumption, the researchers carefully monitored the participants' blood glucose and insulin responses.
Remarkably, results from this innovative study indicated that consuming sweelin® did not elevate blood glucose or insulin levels, even at high doses that equaled the sweetness of substantial sugar intake. These findings provide significant reassurance about the safety of sweelin® for consumers aiming to lower sugar intake without sacrificing flavor, addressing growing health concerns related to high sugar diets.
Amai Proteins initiated this clinical trial not due to regulatory requirements but to enhance consumer confidence and substantiate the health claims surrounding sweelin®. This initiative underscores their commitment to developing solutions that cater to the increasing demand for healthier food options.
The conclusion of this trial marks a significant milestone for Amai Proteins. As a pioneer of novel protein solutions, they are continuously working towards innovation in food technology, linking health benefits with taste. The success of sweelin® aligns with the contemporary dietary trends favoring alternatives that do not compromise the sensory experience of eating.
Looking ahead, Amai Proteins aims to leverage their Pro3 platform to develop further breakthroughs, not just in sweet proteins but across various categories, including meat and plant proteins. Sweelin®, characterized as a 'serendipity berry sweet protein', represents their first major product, designed to replace sugar and its alternatives in a wide array of food and beverage applications.
In a world increasingly focused on health and wellness, Amai Proteins leads the charge with innovative solutions that go beyond mere calorie reduction. Their work signifies a shift towards achieving better dietary choices via science-backed ingredients that promote a healthier lifestyle without sacrificing enjoyment.
For more insights into their pioneering work and the potential of sweelin®, visit Amai Proteins' official platforms or check out the detailed results and media coverage of the recent study.
The study involved twenty healthy participants who underwent three test sessions, during which they consumed beverages sweetened with either sweelin®, glucose, or stevia. Each beverage was meticulously matched for sweetness, equivalent to 75 grams of glucose commonly used in Oral Glucose Tolerance Tests. For 120 minutes post-consumption, the researchers carefully monitored the participants' blood glucose and insulin responses.
Remarkably, results from this innovative study indicated that consuming sweelin® did not elevate blood glucose or insulin levels, even at high doses that equaled the sweetness of substantial sugar intake. These findings provide significant reassurance about the safety of sweelin® for consumers aiming to lower sugar intake without sacrificing flavor, addressing growing health concerns related to high sugar diets.
Amai Proteins initiated this clinical trial not due to regulatory requirements but to enhance consumer confidence and substantiate the health claims surrounding sweelin®. This initiative underscores their commitment to developing solutions that cater to the increasing demand for healthier food options.
The conclusion of this trial marks a significant milestone for Amai Proteins. As a pioneer of novel protein solutions, they are continuously working towards innovation in food technology, linking health benefits with taste. The success of sweelin® aligns with the contemporary dietary trends favoring alternatives that do not compromise the sensory experience of eating.
Looking ahead, Amai Proteins aims to leverage their Pro3 platform to develop further breakthroughs, not just in sweet proteins but across various categories, including meat and plant proteins. Sweelin®, characterized as a 'serendipity berry sweet protein', represents their first major product, designed to replace sugar and its alternatives in a wide array of food and beverage applications.
In a world increasingly focused on health and wellness, Amai Proteins leads the charge with innovative solutions that go beyond mere calorie reduction. Their work signifies a shift towards achieving better dietary choices via science-backed ingredients that promote a healthier lifestyle without sacrificing enjoyment.
For more insights into their pioneering work and the potential of sweelin®, visit Amai Proteins' official platforms or check out the detailed results and media coverage of the recent study.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.